Langasog, Fe L.
HRN: 18-87-84 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/17/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/17/2025
05/29/2025
IV
600mg
Q8H
Sepsis Secondary To Nonhealing Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes